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        Antibody diversifi  cation is achieved through so-
matic remodelling of Ig genes at two distinct 
stages of B cell development. The fi  rst one is 
coupled to B cell diff  erentiation in the bone 
marrow and takes place by V(D)J recombina-
tion, a site-specifi  c recombination reaction that 
is also responsible for antigen receptor diversifi  -
cation in T cells. In contrast to T cells, mature B 
cells that have been stimulated by antigen can 
undergo a secondary antibody diversifi  cation in 
so-called germinal centers, which entails two dis-
tinct molecular mechanisms: somatic hypermu-
tation (SHM) and class switch recombination 
(CSR). SHM introduces nucleotide changes in 
the antigen recognition (i.e., variable region) of 
the Ig genes, thereby allowing the generation of 
antibodies with a higher affi   nity for their cognate 
antigen. CSR is a region-specifi  c recombination 
reaction that replaces the primary      constant 
(C    ) region by a downstream constant region 
(C    , C    , or C    ) that will endow the antibody 
molecule with new eff  ector properties for antigen 
removal (  1  ). Both CSR and SHM are triggered 
by the activity of one enzyme, activation-in-
duced cytidine deaminase (AID) (  2, 3  ). AID ini-
tiates CSR and SHM by deaminating cytosine 
residues on the switch or variable region of the 
Ig genes, respectively (  4  ). AID-induced cytosine 
deamination results in the generation of U:G 
mismatches on Ig DNA that can be processed by 
uracil-N-glycosylase, or of mismatch repair en-
zymes to promote the fi  xation of a mutation 
(SHM) or the generation of a DNA double-
strand break and a subsequent recombination re-
action (CSR; for review see reference   5  ). 
  Most of the lymphomas diagnosed in the 
western world arise from mature B cells and are 
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  Activated B cells reshape their primary antibody repertoire after antigen encounter by two 
molecular mechanisms: somatic hypermutation (SHM) and class switch recombination 
(CSR). SHM and CSR are initiated by activation-induced cytidine deaminase (AID) through 
the deamination of cytosine residues on the immunoglobulin loci, which leads to the gen-
eration of DNA mutations or double-strand break intermediates. As a bystander effect, 
endogenous AID levels can also promote the generation of chromosome translocations, 
suggesting that the fi  ne tuning of AID expression may be critical to restrict B cell lym-
phomagenesis. To determine whether microRNAs (miRNAs) play a role in the regulation of 
AID expression, we performed a functional screening of an miRNA library and identifi  ed 
miRNAs that regulate CSR. One such miRNA, miR-181b, impairs CSR when expressed in 
activated B cells, and results in the down-regulation of AID mRNA and protein levels. We 
found that the AID 3     untranslated region contains multiple putative binding sequences for 
miR-181b and that these sequences can be directly targeted by miR-181b. Overall, our 
results provide evidence for a new regulatory mechanism that restricts AID activity and can 
therefore be relevant to prevent B cell malignant transformation. 
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tracking purposes (  Fig. 1 A  ).   Independent miRNAs were 
retrovirally transduced into primary B cells from wild-type 
mouse spleens, and CSR efficiency to IgG1 isotype in the 
presence of LPS and IL-4 was evaluated (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20080579/DC1). 
We found that expression of miR-181b resulted in the most 
profound decrease of the CSR rate as compared with B cells 
transduced with an empty control vector (55   ±   15%; Fig. 
S1, B and C). This eff  ect was observed after 2 d of miR-
181b expression but became more apparent at later time 
points (  Fig. 1 D  ). Both in the mouse and human genomes, 
two isoforms of miR-181b can be expressed from two dif-
ferent loci. These isoforms are referred to as miR-181b-1 
and miR-181b-2 and are identical in their mature forms, 
but their genomic contexts are slightly diff  erent. We found 
that transduction of either miR-181b-1 or miR-181b-2 
precursors resulted in a similar reduction of CSR (  Fig. 1 B  ). 
miR-181b is member of an miRNA family (miR-181a-d) 
that is highly conserved in vertebrates while being absent 
from other phyla (Fig. S2). Interestingly, overexpression of 
miR-181a-1 or miR-181a-2, whose mature forms diff  er 
from miR-181b  ’  s by only three nucleotides, failed to induce 
a similar eff  ect on the effi   ciency of CSR (  Fig. 1 B  ). These re-
sults indicate that miR-181b expression in primary B cells 
interferes with CSR. 
  CSR is tightly associated with B cell proliferation (  21  ). 
To assess whether miR-181b  –  induced reduction of CSR 
could be caused by a defect in B cell proliferation, we labeled 
B cells with PKH26 dye and analyzed cell division in control- 
and miR-181b  –  expressing cells. We found that B cells trans-
duced with control or miR-181b vectors display very similar 
profi  les of proliferation at all time points analyzed (  Fig. 1 E  ). 
Similar proliferative activity was also found by analyzing 
the percentage of GFP  +   cells throughout the cultures (Fig. 
S3 A, available at http://www.jem.org/cgi/content/full/
jem.20080579/DC1). In addition, no signifi  cant diff  erences 
in cell survival or plasma cell generation were observed in 
miR-181-b versus control-transduced B cells (Fig. S3, B and C). 
Therefore the CSR impairment induced by miR-181b is not 
caused by defective proliferation, altered survival, or enhanced 
plasma cell diff  erentiation. 
  To assess the miRNA expression profi  le of CSR-stimu-
lated B cells, we performed array analysis of LPS + IL-4  –  acti-
vated versus mature resting B cells. B cell activation resulted 
in a shift of miRNA expression featuring the down-regulation 
of a large number of miRNAs and a dramatic increase of a re-
duced number of miRNAs, including miR-155 and miR-217 
(Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20080579/DC1), whose expression has been associated 
with B cell neoplasias. Interestingly, our array analysis showed 
that miR-181b is down-regulated in stimulated compared 
with nonstimulated B cells (Fig. S4). To confi  rm this observa-
tion, we analyzed miR-181b expression in B cells at diff  erent 
time-points of LPS + IL-4 cultures both by Northern blotting 
and by real-time PCR (  Fig. 1, F and G;   and Fig. S5). We 
found that mature miR-181b expression is highest at day 0, 
characterized by the presence of chromosome translocations 
that involve one of the Ig loci and a protooncogene (  6  ). AID 
has been shown to be required for the generation in vivo of 
  c-myc  /  IgH   lymphomagenic translocations, analogous to those 
found in human Burkitt lymphomas (  7, 8  ). AID promotes 
  c-myc  /  IgH   translocations in a deaminase- and uracil-N-glyco-
sylase  –  dependent fashion, which indicates that CSR and 
  c-myc  /  IgH   chromosome translocations are initiated through a 
common mechanism (  9  ). In addition, AID can mutate a sig-
nifi  cant number of genes expressed in germinal center B cells, 
including the protooncogenes   Bcl-6  ,   c-myc  , and   Pim1   (  10, 11  ). 
Moreover, AID lymphomagenic potential has been revealed in 
IL-6  –   (  7  ), myc- (  12  ), Bcl6- (  13  ), and pristane-induced (  14  ) B 
cell neoplasias. 
  Several mechanisms have been proposed to regulate AID 
expression and function and, expectedly, to reduce the risk 
of unwanted DNA damage. These mechanisms include the 
restriction of AID activity or of mutagenic resolution mostly 
to Ig DNA sequences, limiting AID nuclear concentration 
by regulation of its subcellular localization and phosphoryla-
tion (for review see reference   15  ). Regarding the regulation 
of AID expression, although it is mostly restricted to acti-
vated B cells, recent fi  ndings have shown that low expres-
sion levels can be detected in immature B cells, in response 
to some viral infections, and occasionally in non  –  B cells, at 
least in certain infl  ammation-associated neoplasic situations 
(for review see reference   16  ). 
  MicroRNAs (miRNAs) are small noncoding RNA mol-
ecules that can regulate gene expression by aff  ecting either 
the stability or the translation effi   ciency of their target mRNAs. 
Gene expression regulation by miRNAs has been involved in 
several processes that include development and diff  erentiation, 
cell proliferation, cell death, and neoplasic transformation 
(  17  ). In addition, miRNA expression analysis of diff  erent 
neoplasias, particularly lymphomas, has revealed specifi  c pro-
fi  les associated with particular malignancies (  18, 19  ). Recently, 
miRNAs have been shown to regulate some aspects of nor-
mal B cell diff  erentiation and function. miR-181a promotes 
B cell diff  erentiation in the bone marrow, miR-155 is involved 
in the generation of germinal center and plasma B cells, and 
miR-150 controls B cell development and response through 
the regulation of c-Myb transcription factor (for review see 
reference   20  ). However, the role of miRNAs in the regulation 
of AID-dependent reactions in activated B cells has not been 
specifi  cally addressed. In this work, we have screened for 
miRNAs involved in the regulation of CSR and have identifi  ed 
miR-181b, which regulates AID expression posttransciption-
ally in B cells. 
    RESULTS AND DISCUSSION   
  miR-181b expression impairs the CSR reaction 
  To determine whether specifi  c miRNAs are involved in the 
regulation of the CSR reaction, we performed a functional 
screen of an miRNA expression library containing 150 clones. 
miRNA sequences, including their genomic context, were 
cloned into a retroviral vector harboring a GFP cassette for JEM VOL. 205, September 29, 2008  2201
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fore that it restores miR-181b levels found in resting, mature 
B cells. We conclude that miR-181b decreases CSR effi   ciency 
and that its expression is down-regulated upon B cell activation. 
miR181 miRNAs are predominantly expressed in the lym-
phoid system (  19  ) (for review see reference   20  ), and miR-181a 
drops at day 1 (mean = 18   ±   7%), and increases moderately 
later to reach     50% of initial levels after 3 d of culture (  Fig. 1 G  ). 
Quantitative analysis of miR-181b expression in transduced B 
cells showed that our miRNA overexpression assay yielded a 
3.3   ±   2.9-fold increase at day 3 of culture (Fig. S6), and there-
    Figure 1.         miR-181b expression reduces CSR effi  ciency.   (A) Representation of the pre-miRNA  –  GFP retroviral vector. (B) miR-181b-1 and -2 isoforms, 
but not miR-181a-1 or -2 isoforms, decrease CSR. Primary B cells were activated with LPS + IL-4 and were transduced with vectors containing the indi-
cated pre-miRNAs (x axis). CSR effi  ciency was measured by FACS analysis of IgG1 expression 4 d after retroviral transduction. Bars indicate the mean 
percentage of IgG1  +   cells within the subset of GFP  +  , transduced cells, normalized to the value obtained in control-transduced cells. Error bars show the 
SD values in each case. p-values versus control-transduced cells (paired two-tailed   t   test) are indicated below (  n   = 14 for miR-181b-1; and   n   = 5 for miR-
181b-2, miR181a-1, and miR181a-2 isoforms). (C) miR-181b reduces CSR effi  ciency. B cells were activated and transduced as in B. IgG1 CSR effi  ciency of 
B cells transduced with control (left) or miR-181b (right) pre-miRNA retroviral vectors was analyzed by fl  ow cytometry after 4 d in culture in the presence 
of LPS + IL-4. Analysis of IgG1/B220 expression gated on GFP  +   cells from three independent representative experiments is shown. Percentages indicate 
the proportion of IgG1  +   (within the GFP  +   transduced population) in the displayed gates. (D) Time-course analysis of IgG1 CSR effi  ciency of control- and 
miR-181b  –  transduced B cells in LPS + IL-4 cultures. Means from seven independent experiments are represented. Vertical bars show the SD values at 
each time point. (P = 0.003, day 3 vs. control using a paired two-tailed   t   test; P   <   0.0001, day 4 vs. control). (E) miR-181b does not affect B cell prolifera-
tion. Splenic B cells were labeled with PKH26, and were activated and transduced as in B. The proliferation of transduced cells was assessed by measuring 
PKH26 dilution in GFP  +   cells after 2 (top), 3 (middle), or 4 (bottom) d of LPS + IL-4 stimulation. Histograms show representative fl  ow cytometry profi  les of 
PKH26 (continuous line, control-transduced cells; dashed line, miR-181b  –  transduced cells). Bars underneath the histograms show the percentage of cells 
that have undergone each of the indicated cell divisions, as calculated with ModFit software (black bars, control-transduced cells; white bars, miR-181b  –
  transduced cells). Error bars show SD values (  n   = 2). (F) miR-181b expression is regulated upon B cell activation. RNA from splenic B cells was analyzed by 
Northern blotting at days 0, 1, 2, and 3 of LPS + IL-4 stimulation for the expression of miR-181b (top gel). Expression of U6 RNA from the same samples 
is shown as a loading control (bottom gel). (G) Quantifi  cation of mature miR-181b expression in B cells. RNA was isolated as in F and retrotranscribed, 
and mature miR-181b was amplifi  ed by real-time PCR. Bars show the amount of miR-181b (in zeptomole/ng RNA) at each time point as calculated with 
an miRNA reference panel (Fig. S5, available at http://www.jem.org/cgi/content/full/jem.20080579/DC1). Error bars show the SD values (  n   =  3).   2202 AID REGULATION BY   MI R-181 B     | de Y  é  benes et al. 
  We next aimed at evaluating the content of miR-181b 
seed sequences within down-regulated mRNAs. miRNAs are 
21  –  23 long RNA molecules that exert their negative regula-
tory role by imperfect base pairing with sequences of target 
mRNAs, mostly present in their 3     untranslated regions 
(UTRs) (  17  ). The most signifi  cant contribution for target rec-
ognition involves the six to eight nucleotides located in the 5     
end of the miRNA, and it is termed seed sequence (  22  ). To 
identify putative miR-181b targets, we assessed the presence 
of minimal seed complementation in the 3    UTRs of miR-
181b  –  down-regulated mRNAs, as defi  ned by containing 
the sequences 5    -GAATGT-3    , 5    -AATGTT-3    , or 5    -
TGAATG-3     (  23  ). This analysis resulted in the identifi  cation 
of 93 known transcripts whose expression is down-regulated 
upon miR-181b expression and which contain miR-181b 
seed sequences in their 3    UTRs (  Fig. 2 A  ; for a complete list, 
see Table S2, available at http://www.jem.org/cgi/content/
full/jem.20080579/DC1). We found that AID is one of the 
most down-regulated mRNAs that contains seed sequences 
for miR-181b (  Table I  ).   To assess whether putative miR-
181b binding sites in AID mRNA are phylogenetically con-
served, we analyzed AID 3    UTR sequences from the human, 
dog, and zebrafi  sh. There is no experimental data on the rat 
AID 3    UTR sequence, and only a 60-nucleotide long ex-
pressed sequence tag from the chicken 3    UTR, which lacks a 
polyA sequence, is found in the databases, very likely refl  ect-
ing that this UTR is not complete. Therefore, we made use of 
the Ensembl Genome Browser to predict chicken and rat AID 
3    UTRs. We found conserved putative miR-181b seed se-
quences in experimental AID 3    UTR sequences from the hu-
man, dog, and zebrafi  sh, as well as in predicted AID 3    UTR 
sequences from the rat and chicken (  Fig. 2 B  ). This analysis 
suggests that the miR-181b binding site in the AID 3    UTR is 
evolutionarily conserved. 
  To confi  rm the down-regulation data obtained by array 
analysis, we performed real-time RT-PCR and found a con-
sistent decrease in AID levels in miR-181b  –  transduced when 
compared with control-transduced primary B cells (32% re-
duction; P = 0.004;   Fig. 2 C  ). Similar results were obtained 
in the Ramos Burkitt lymphoma cell line (not depicted) or 
when protein levels were analyzed by Western blotting (52   ±   
8%;   Fig. 2 D  ). In contrast, a reduction of AID levels was not 
observed in B cells transduced with miRNAs 19b, 30b, or 
149 (Fig. S7, available at http://www.jem.org/cgi/content/
full/jem.20080579/DC1), indicating that this eff  ect is specifi  c 
for miR-181b. We conclude that miR-181b expression in 
CSR-activated primary B cells results in the down-regulation 
of AID both at the mRNA and protein levels, and that the 
AID 3    UTR contains putative binding sites for miR-181b. 
The observed AID reduction is physiologically relevant, as 
we have found that AID expression level in activated B cells 
is limiting both for the CSR reaction and for the generation 
of   c-myc  /  IgH   chromosome translocations, as revealed in AID  +/      
mice (unpublished data). Therefore, AID down-regulation 
induced by miR-181b can account for the observed reduc-
tion in CSR. 
has been shown to promote B cell diff  erentiation and to fi  ne 
tune the activation thresholds of thymocytes (for review see 
reference   [20]  ). These fi  ndings suggest that the miR-181 fam-
ily can have an evolutionarily conserved role in the regulation 
of adaptive immunity. 
  Identifi  cation of miR-181b mRNA targets 
  To gain insights into the putative mRNA targets of miR-
181b, we profi  led mRNA expression shifts upon miR-181b 
expression. Splenic B cells were transduced with miR-181b 
or control vectors, and RNA from LPS + IL-4  –  stimulated, 
GFP  +   cells was used to hybridize oligonucleotide arrays. 
Within the 760 informative spots (  n   = 3; P   <   0.1), 21% were 
found to be down-regulated in miR-181b  –  expressing cells 
when compared with control cells (  Fig. 2 A  ; for a complete 
list of down-regulated transcripts, see Table S1, available at 
http://www.jem.org/cgi/content/full/jem.20080579/DC1).   
    Figure 2.         AID expression is reduced in cells overexpressing miR-
181b.   (A) Representation of differentially expressed genes in control- 
versus miR-181b  –  transduced B cells analyzed by cDNA microarray 
analysis. 157 out of 760 transcripts were reduced in miR-181b  –  trans-
duced cells (P   ≤   0.1; expression difference   ≤   0.95-fold). 93 of the down-
regulated transcripts contained miR-181b seeds within their 3   UTR 
sequences. (B) miR-181b binding site in the AID 3    UTR is evolutionarily 
conserved. The diagram shows the alignment of miR-181b (top, shown in 
its reverse orientation) and its putative binding sites in human (hu), dog 
(do), mouse (mo), and zebrafi  sh (ze) experimental AID 3    UTRs as well as in 
the predicted rat (ra)* and chicken (ch)* UTRs . Conserved nucleotides are 
shaded, conserved nucleotides at the seed sequence are bolded. (C) AID 
mRNA levels are reduced in miR-181b  –  expressing cells. Primary B cells 
were retrovirally transduced with miR-181b or control vectors, GFP  +   cells 
were sorted by fl  ow cytometry after 3 d of LPS + IL-4 stimulation, and 
AID expression levels were determined by real-time RT-PCR. Error bars 
show SD (  n   = 4; P = 0.0044). (D) AID protein level is reduced in miR-
181b  –  expressing cells. One-third dilutions of total lysates from GFP  +   miR-
181b  –   or control-transduced primary B cells were analyzed by Western 
blotting. Lysates from LPS + IL-4  –  stimulated wild-type (+) and AID     /     (  ) 
B cells were included as controls. Molecular masses are indicated. Quanti-
fi  cation after blot densitometry and normalization is shown (bottom). 
Error bars represent SD values (  n   =  3).   JEM VOL. 205, September 29, 2008  2203
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  AID mRNA levels are low in resting B cells and dra-
matically increase 2 d after stimulation with LPS + IL-4 
(Fig. S10, available at http://www.jem.org/cgi/content/full/
jem.20080579/DC1). In contrast, miR-181b levels are high-
est in nonstimulated cells, drop upon stimulation, and increase 
steadily afterward (  Fig. 1, F and G  ). While this manuscript was 
under review, two reports have shown that AID 3    UTR con-
tains functional sites for miR-155 (  24, 25  ), an miRNA with 
pleiotropic eff  ects on B cell function, including plasma cell 
generation and lymphomagenesis (for review see reference  20  ). 
Removal of the miR-155 site from the AID 3    UTR results 
  AID is a direct target for miR-181b 
  To assess whether miR-181b promotes AID down-regula-
tion by direct targeting of its 3    UTR, we performed lucifer-
ase reporter analysis. Alignment analysis showed that mouse 
and human AID 3    UTRs in fact contain multiple putative bind-
ing sequences for miR-181b (Fig. S8, available at http://
www.jem.org/cgi/content/full/jem.20080579/DC1). Lucif-
erase constructs were developed that contain each of the 
miR-181b putative binding sites identified in the mouse 
AID 3    UTR (BS1-3), or mutated versions of the same 
(mutBS1-3). Reporter constructs, which included a fi  refl  y 
luciferase cassette to allow internal Renilla luciferase activity 
normalization, were transiently cotransfected together with 
miR-181b duplexes into 293T cells, and luciferase activity 
was analyzed 24 h later (Fig. S9 shows raw values of lucifer-
ase measurements). We found that transfection of the BS1 
and BS2 constructs in the presence of miR-181b resulted in 
a signifi  cant decrease of luciferase activity when compared 
with their mutant counterparts mutBS1 (85   ±   9%) and BS2 
(45   ±   9%;   Fig. 3 A  ), whereas transfection of BS3 did not af-
fect luciferase activity (Fig. S9 and not depicted).   Besides 
AID, we have found that miR-181b expression results in 
the down-regulation of several genes, a subset of which con-
tain minimal seed sequences for miR-181b in their 3    UTRs. 
Although we cannot rule out that other target genes could 
play a minor role in the CSR impairment induced by miR-
181b, none of these genes are known to directly participate 
in the CSR reaction. 
  Finally, to address whether miR-181b could play a physi-
ological role in the control of AID expression in B cells, we 
analyzed miR-181b and AID expression by real-time PCR 
in a collection of Burkitt, mantle cell lymphoma, and diff  use 
B cell lymphoma human B cell lines. None of the lymphoma 
cell lines were found to coexpress high levels of AID and 
miR-181b (  Fig. 3 C  ), which indeed suggests that high ex-
pression of miR-181b may prevent the accumulation of high 
amounts of AID transcripts. 
    Table I.        Most down-regulated genes with miR-181b seed 
sequences in activated B cells upon expression of miR-181b 
Gene Fold versus control p-value
  Slc35d3 0.32 0.1
  Ak3l1 0.4 0.01
  Ndrg1 0.46 0.07
  Pitpnc1 0.57 0.07
  Tmem14a 0.63 0.08
  Cd244 0.65 0.04
  Gch1 0.65 0.05
  Errfi  1 0.66 0.06
  Hk2 0.67 0.02
  Mxi1 0.67 0.02
  Ccdc58 0.67 0.04
  Sc4mol 0.69 0.03
  Pfkfb3 0.69 0.04
  Pdxp 0.69 0.05
  Atp5g1 0.69 0.09
  Casp3 0.7 0.05
  Aicda 0.7 0.05
  Ulk3 0.7 0.07
  Snx25 0.71 0.09
  Higd1a 0.71 0.09
    Figure 3.         AID is a direct target of miR-181b.   (A) Luciferase reporter assays of NIH-293T cells transfected with luciferase constructs containing 
AID  –  miR-181b putative binding sites. Cells were cotransfected with miR-181b miRNA duplexes along with wild-type (BS1 and BS2) or mutated ver-
sions (mutBS1 and mutBS2) of the miR-181b putative binding sites in the mouse AID 3    UTR. The sequences included in each luciferase construct are 
shown in Table S3 (available at http://www.jem.org/cgi/content/full/jem.20080579/DC1). Bars represent luciferase activity for each of the binding sites 
relative to their mutated counterparts (for raw data see Fig. S9). Statistical bars show SDs. P-values (paired two-tailed   t   test) are shown. (B) miR-181b 
and AID mRNA expression assessed by quantitative RT-PCR in Burkitt (closed triangles), diffuse large B cell lymphoma (closed circles), and Mantle cell 
lymphoma (open diamonds) human B cell lines. The expression of miR-181b and AID was normalized to their expression in primary human B cells, 
which has been given an arbitrary value of 1.     2204 AID REGULATION BY   MI R-181 B     | de Y  é  benes et al. 
roviral supernatants were produced by transient calcium phosphate transfec-
tion of NIH-293T cells with pCL-ECO (Imgenex) and pre-miRNA GFP 
retroviral vectors. Mouse primary B cells were transduced with retroviral su-
pernatants for 20 h in the presence of 8   μ  g/ml polybrene (Sigma-Aldrich), 
25   μ  g/ml LPS, and 10 ng/ml IL-4. 
  FACS analysis and cell sorting.     Transduced B cells were labeled with 
anti-B220  –  PE antibody or anti-CD138  –  PE antibody, anti-IgG1 biotin anti-
body, allophycocyanin-streptavidin, and 7-aminoactinomycin D (BD Biosci-
ences), and were analyzed in a fl  ow cytometer (FACSCanto; BD Biosciences) 
at the time points indicated in the fi  gures. For proliferation analysis, cells were 
labeled before transduction with 4   μ  M PKH26 (Sigma-Aldrich), according to 
the manufacturer  ’  s instructions. miR-181b  –   or control-transduced B cells 
were sorted at diff  erent time points after retroviral transduction based on GFP 
expression. Activated B cells for miRNA array analysis were obtained after 
CFSE labeling (Invitrogen), LPS + IL-4 stimulation for 3 d, and sorting of 
cells that had undergone at least one cell division. Sortings were performed 
with a cell sorter (FACSAria; BD Biosciences). Primary human B cells were 
isolated by centrifugation in Ficoll density gradient (GE Healthcare) and im-
munomagnetic cell sorting of CD19  +   cells (Miltenyi Biotec). 
  Quantitative PCR, Northern blotting, and Western blotting.     RNA 
was extracted with TRI  zol   (Invitrogen) and converted into cDNA using 
random primers (Roche) and SuperScript II reverse transcriptase (Invit-
rogen). Human and mouse AID mRNA were quantifi  ed using an SYBR 
green assay (Applied Biosystems). GAPDH amplifi  cations were used as nor-
malization controls. The primers used were as follows: (forward) 5-   accttcgc-
aacaagtctggct-3     and (reverse) 5-    agccttgcggtcttcacagaa-3     for mouse   Aicda  , 
(forward) 5   -cctcttgatgaaccggaggaa-3     and (reverse) 5   -agcactgtcacgcctct-
tcact-3     for human   Aicda  , (forward) 5    -tgaagcaggcatctgaggg-3     and (reverse) 
5    -cgaaggtggaagagtgggag-3     for mouse GAPDH, and (forward) 5    -gaaggtga-
aggtcggagtc-3     and (reverse) 5    -gaagatggtgatgggatttc-3     for human GAPDH. 
For miR-181b real-time PCR, RNA was extracted with TRI  zol   and re-
verse-transcribed with an miR-181b  –  specifi   c primer using the TaqMan 
miRNA RT system (Applied Biosystems). Quantitative PCR of miR-181b 
was performed using miR-181b  –  specifi  c primers and a TaqMan probe (Ap-
plied Biosystems). Amplifi  cation of U18 (for human samples) or sno-142 
(for mouse samples) using specifi  c primers and a TaqMan probe was used 
as a normalization control. Serial dilutions of a mixture of synthetic RNA 
oligonucleotides of known concentration (Applied Biosystems) were used 
as a reference to titrate miR-181b amplifi  cations by real-time RT-PCR. 
Quantitative PCRs were performed on 7900HT fast real-time PCR system 
(Applied Biosystems). Northern blots were performed using 10   μ  g of total 
RNA. Hybridizations were performed with a 5   -end radiolabeled anti –  miR-
181b LNA probe (Exiqon) and an anti-U6 DNA probe. Band size was de-
termined with a radiolabeled 10-bp RNA decade marker (Ambion). Lysates 
for protein analysis were prepared in Nonidet P-40 buff  er in the presence of 
protease inhibitors (Roche). 40, 13.3, or 4.4   μ  g of lysate were analyzed by 
Western blotting, as previously described (  29  ), using an anti-AID polyclonal 
antibody (provided by K.M. McBride, The Rockefeller University, New 
York, NY) or an anti  –      -tubulin antibody (Sigma-Aldrich). Western blot 
quantifi  cation was performed using Odyssey software. 
  Microarray analysis.     miRNA microarray experiments were performed 
with paired samples of nonstimulated and stimulated B cells sorted as de-
scribed in FACS analysis and cell sorting. RNA was isolated with TRI  zol  . 
miRNA microarray hybridizations were done on slides containing dupli-
cate probes corresponding to 326 human and 249 mouse miRNA genes, as 
previously described (  30  ). Computational analysis of miRNA microarray 
data was performed as previously described (  30  ). In brief, blank and probe 
control spots were removed and local background was subtracted from the 
median signal. Signal intensity was transformed to a log2 scale, and spots 
whose intensities were lower than 99th percentile of blank spots were re-
moved. Diff  erentially expressed genes were selected using a signifi  cance 
analysis of microarrays algorithm. Microarray experiments for mRNA ex-
pression analysis were performed with RNA from mouse primary B cells 
in an increase of AID levels, slightly enhances CSR, and pro-
motes   c-myc  /  IgH   translocations (  24, 25  ). miR-155 transduc-
tion failed to reduce CSR effi   ciency in our overexpression 
assay (Fig. S1), most likely because of the high levels of this 
miRNA already present in activated B cells. It is tempting to 
speculate that miR-181b and miR-155 have nonoverlapping 
functions in regulating AID expression, with miR-181b pre-
venting premature AID activity while allowing proper AID 
transcriptional activation at early time points and with miR-
155 narrowing its function at a later activation stage. 
  This work provides evidence for a new role of miRNAs 
in the control of the CSR reaction. We have shown that there 
is a diff  erential miRNA expression profi  le in B cells undergoing 
CSR that shares remarkable similarities with miRNA profi  les 
in human cancers, including overall miRNA down-regula-
tion (  26  ) and a dramatic increase of very few miRNAs whose 
expression has been linked to B cell neoplasias. This observa-
tion may refl  ect that miRNAs contribute to the transforma-
tion propensity that seems associated with germinal center B 
cells. miRNA functional screening combined with miRNA 
profi  ling has allowed to identify miR-181b as a negative regu-
lator of the CSR reaction that directly targets AID. Consistent 
with this observation, miR-181b expression is reduced upon 
B cell activation, presumably allowing optimal effi   ciency of 
this reaction within the appropriate time window. miR-181b 
expression yields a moderate decrease of AID levels, which is 
nevertheless suffi   cient to promote a proportional impairment 
of CSR effi   ciency. This fi  ne-tune regulatory mechanism 
highlights the importance of miRNAs in keeping the ex-
pression of target genes within narrow, physiological levels, as 
previously suggested (  27  ). By limiting AID expression, miR-
181b could act as a tumor suppressor miRNA in B cells. In 
support of this hypothesis, miR-181b has been shown to tar-
get the   Tcl-1   oncogene in B cell chronic lymphocytic leuke-
mia, and the loss of miR-181b expression has been shown 
to be associated to the aggressive form of chronic lymphocytic 
leukemia (  28  ). 
  In summary, we have identifi  ed miR-181b as a modula-
tor of endogenous AID expression. This fi  nding represents a 
novel, posttranscriptional regulatory mechanism of AID ac-
tivity in B cells that may be involved in restricting the lym-
phomagenic potential associated with this reaction. 
  MATERIALS AND METHODS 
  Cell cultures.     The NIH-293T cell line was cultured in 10% FCS DMEM. 
Burkitt lymphoma (Akata, Boston, Ramos, Namalwa, Raji, and Daudi), 
diff  use large B cell lymphoma (DB, Oci-Ly19, Su-dhl4, Su-DHl6, and 
Toledo) and mantle B cell lymphoma (Irm2, Jeko1, Jvm2, Upn1, and 
Upn2) cell lines were cultured in 10% FCS RPMI 1640 medium. Mouse 
primary B cells were purifi  ed from the spleens of C57/BL6 mice by anti-
CD43 immunomagnetic depletion (Miltenyi Biotec) and were cultured in 
25   μ  g/ml LPS (Sigma-Aldrich), 10 ng/ml IL-4 (PeproTech), 10 mM Hepes 
(Invitrogen), 50   μ  M     -mercaptoethanol (Invitrogen), and 10% FCS RPMI 
1640 medium. 
  miRNA library and retroviral infection.     DNA fragments containing 
150 pre-miRNAs and their fl  anking 50-bp-long genomic sequences were 
cloned in XhoI-EcoRI sites of the pre-miRNA GFP vector (  Fig. 1 A  ). Ret-JEM VOL. 205, September 29, 2008  2205
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transduced with control and miR-181b after sorting of GFP  +   cells, as de-
scribed above. Gene expression profi  ling was performed by hybridization 
to a mouse 44K probe platform (Agilent Technologies). Genes with a p-
value of   ≤  0.1 and a   ≤  0.95 fold expression diff  erence were selected for fur-
ther analysis. Microarray data have been deposited in the Gene Expression 
Omnibus under accession no.   GSE12186  . To examine the presence of po-
tential miR-181b   “  seeds  ”   within the 3    UTR sequences of down-regulated 
transcripts in miR-181b  –  transduced cells, a computational miRNA target 
search was performed, as previously described (  23  ). In brief, down-regu-
lated genes were mapped to known transcripts in the Ensembl Genome 
Browser (version 45; available at http://www.ensembl.org/index.html) us-
ing the Ensembl Perl API, and a custom Perl script was then used to search 
for putative miR-181b target sites, defi  ned by complete sequence comple-
mentarity between a hexamer in the 3    UTR sequence of the transcript and 
the miRNA seed (positions 1  –  8 of the 5     end) (  22  ). 
  Sequence alignments.     Motifs complementary to miR-181b seed were 
searched within   Aicda   3    UTR sequences from diff  erent species using SeqMan 
software. Human, mouse, dog, and zebrafi  sh   Aicda   3    UTRs were retrieved 
from the Ensembl database (Ensembl rl. 49). Predicted chicken and rat   Aicda   
3    UTRs were obtained by a 3     extension of their CDS sequence up to 1,200 bp 
with genomic sequences retrieved from the Ensembl Genome Browser. 
  Luciferase assays.     Luciferase reporter constructs were made by ligating 
30-bp-long synthetic oligonucleotides containing putative miR-181b bind-
ing sites from the mouse AID 3    UTR or their mutant versions (Table S3, 
available at http://www.jem.org/cgi/content/full/jem.20080579/DC1) in 
XhoI-NotI sites of the psiCheck-2 vector (Promega). Cloning was verifi  ed 
by sequencing. Reporter assays were performed in NIH-293T cells cotrans-
fected in duplicates with Lipofectamine 2000 (Invitrogen) with each inde-
pendent luciferase reporter plasmid along with miR-181b duplex (Applied 
Biosytems) at a fi  nal concentration of 100 nM. Firefl  y luciferase expression 
was used as a normalization control. Reporter activity was detected 24 h 
after transfection with the Dual-Glo Luciferase Assay System (Promega) in a 
Glomax reader (Promega). 
  Online supplemental material.     Fig. S1 shows the functional screening of 
an miRNA library. Fig. S2 depicts the conservation of paralogous miR-181 
sequences. Fig. S3 shows that miR-181b expression does not aff  ect cell pro-
liferation or survival, or plasma cell diff  erentiation. Fig. S4 depicts diff  eren-
tially expressed miRNAs in activated B cells. Fig. S5 shows miR-181b 
quantifi  cation by real-time RT-PCR with an miRNA reference panel. Fig. 
S6 depicts miR-181b expression in transduced primary B cells. Fig. S7 shows 
that AID mRNA levels are specifi  cally reduced in B cells overexpressing 
miR-181b. Fig. S8 depicts putative miR-181b binding sites in human and 
mouse AID 3    UTRs. Fig. S9 depicts luciferase reporter assays of putative 
miR-181b binding sites in the mouse AID 3    UTR. Fig. S10 shows AID ex-
pression in LPS + IL-4  –  stimulated primary B cell cultures. Table S1 shows 
down-regulated mRNAs in activated B cells that express miR-181b. Table 
S2 shows down-regulated mRNAs containing miR-181b seed sequences in 
activated B cells that express miR181b. Table S3 provides sequences cloned 
in the psiCheck-2 vector. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20080579/DC1. 
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